Skip to Content


In the US, Mylotarg (gemtuzumab systemic) is a member of the drug class CD33 monoclonal antibodies and is used to treat Acute Myeloid Leukemia.

US matches:

Ingredient matches for Mylotarg


Gemtuzumab ozogamicin (a derivative of Gemtuzumab) is reported as an ingredient of Mylotarg in the following countries:

  • France
  • Japan

Important Notice: The international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.